{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:37:12Z","timestamp":1781559432305,"version":"3.54.5"},"reference-count":34,"publisher":"Japanese Circulation Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1253\/circj.cj-13-0220","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T22:58:05Z","timestamp":1379113085000},"page":"2898-2903","source":"Crossref","is-referenced-by-count":15,"title":["Amiodarone-Induced Thyrotoxicosis Late After Amiodarone Withdrawal"],"prefix":"10.1253","volume":"77","author":[{"given":"Atsuhiko","family":"Yagishita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hachiya","sequence":"additional","affiliation":[{"name":"Heart Rhythm Center, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Heart Rhythm Center, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Sasano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Hirao","sequence":"additional","affiliation":[{"name":"Heart Rhythm Center, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":" 1. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation investigators. N Engl J Med 2000; 342: 913–920.","DOI":"10.1056\/NEJM200003303421302"},{"key":"2","doi-asserted-by":"crossref","unstructured":" 2. Kurita T, Motoki K, Yasuoka R, Hirota T, Akaiwa Y, Kotake Y, et al. Rhythm control should be better for the management of patients with atrial fibrillation and heart failure: Rhythm control vs. rate control. Which is better in the management of atrial fibrillation? (rhythm-side). Circ J 2011; 75: 979–985.","DOI":"10.1253\/circj.CJ-11-0075"},{"key":"3","doi-asserted-by":"crossref","unstructured":" 3. Chinushi M, Iijima K. Rate control is a better initial treatment for patients with atrial fibrillation and heart failure: Rhythm control vs. rate control. Which is better in the management of atrial fibrillation? (rate-side). Circ J 2011; 75: 970–978.","DOI":"10.1253\/circj.CJ-11-0080"},{"key":"4","doi-asserted-by":"crossref","unstructured":" 4. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The optic study. A randomized trial. JAMA 2006; 295: 165–171.","DOI":"10.1001\/jama.295.2.165"},{"key":"5","doi-asserted-by":"crossref","unstructured":" 5. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63–73.","DOI":"10.7326\/0003-4819-126-1-199701010-00009"},{"key":"6","doi-asserted-by":"crossref","unstructured":" 6. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30: 791–798.","DOI":"10.1016\/S0735-1097(97)00220-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":" 7. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: Risk factors in adults with congenital heart disease. Circulation 1999; 100: 149–154.","DOI":"10.1161\/01.CIR.100.2.149"},{"key":"8","doi-asserted-by":"crossref","unstructured":" 8. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 1996; 81: 2930–2933.","DOI":"10.1210\/jcem.81.8.8768854"},{"key":"9","doi-asserted-by":"crossref","unstructured":" 9. Bogazzi F, Bartalena L, Dell’Unto E, Tomisti L, Rossi G, Pepe P, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in italy. Clin Endocrinol (Oxf) 2007; 67: 533–537.","DOI":"10.1111\/j.1365-2265.2007.02920.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Martino E, Bartalena L, Mariotti S, Aghini-Lombardi F, Ceccarelli C, Lippi F, et al. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol 1988; 119: 167–173.","DOI":"10.1530\/acta.0.1190167"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli A, et al. Color flow doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997; 7: 541–545.","DOI":"10.1089\/thy.1997.7.541"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Martino E, Macchia E, Aghini-Lombardi F, Antonelli A, Lenziardi M, Concetti R, et al. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis? Clin Endocrinol (Oxf) 1986; 24: 627–633.","DOI":"10.1111\/j.1365-2265.1986.tb01658.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Conen D, Melly L, Kaufmann C, Bilz S, Ammann P, Schaer B, et al. Amiodarone-induced thyrotoxicosis: Clinical course and predictors of outcome. J Am Coll Cardiol 2007; 49: 2350–2355.","DOI":"10.1016\/j.jacc.2007.02.054"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab 2009; 94: 109–114.","DOI":"10.1210\/jc.2008-1907"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kurt IH, Yigit T, Karademir BM. Atrial fibrillation due to late amiodarone-induced thyrotoxicosis. Clin Drug Invest 2008; 28: 527–531.","DOI":"10.2165\/00044011-200828080-00008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Minelli R, Gardini E, Bianconi L, Salvi M, Roti E. Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: The subsequent phases of thyroid function in a patient chronically treated with amiodarone. J Endocrinol Invest 1992; 15: 853–855.","DOI":"10.1007\/BF03348819"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: A common source of iodine-induced thyrotoxicosis. Horm Res 1987; 26: 158–171.","DOI":"10.1159\/000180696"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Loh KC. Amiodarone-induced thyroid disorders: A clinical review. Postgrad Med J 2000; 76: 133–140.","DOI":"10.1136\/pmj.76.893.133"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sato K, Miyakawa M, Eto M, Inaba T, Matsuda N, Shiga T, et al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J 1999; 46: 443–451.","DOI":"10.1507\/endocrj.46.443"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Brennan MD, Erickson DZ, Carney JA, Bahn RS. Nongoitrous (type i) amiodarone-associated thyrotoxicosis: Evidence of follicular disruption in vitro and in vivo. Thyroid 1995; 5: 177–183.","DOI":"10.1089\/thy.1995.5.177"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 1987; 11: 197–204.","DOI":"10.1097\/00000478-198703000-00004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Leung WH, Pun KK, Lau CP, Wong CK, Wang C. Amiodarone-induced thyroiditis. Am Heart J 1989; 118: 848–849.","DOI":"10.1016\/0002-8703(89)90602-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Meurisse M, Hamoir E, D’Silva M, Joris J, Hennen G. Amiodarone-induced thyrotoxicosis: Is there a place for surgery? World J Surg 1993; 17: 622–626.","DOI":"10.1007\/BF01659125"},{"key":"24","unstructured":"24. Mulligan DC, McHenry CR, Kinney W, Esselstyn CB Jr. Amiodarone-induced thyrotoxicosis: Clinical presentation and expanded indications for thyroidectomy. Surgery 1993; 114: 1114–1119."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 1994; 134: 2277–2282.","DOI":"10.1210\/endo.134.5.8156930"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840–847.","DOI":"10.1016\/0002-8703(83)90006-6"},{"key":"27","unstructured":"27. Primeau R, Agha A, Giorgi C, Shenasa M, Nadeau R. Long term efficacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol 1989; 5: 98–104."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Albert SG, Alves LE, Rose EP. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 1987; 9: 175–183.","DOI":"10.1016\/S0735-1097(87)80098-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507–511.","DOI":"10.1016\/0002-9343(91)90187-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240–254.","DOI":"10.1210\/edrv.22.2.0427"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Roti E, Minelli R, Gardini E, Bianconi L, Braverman LE. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone: A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993; 153: 886–892.","DOI":"10.1001\/archinte.153.7.886"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Roti E, Minelli R, Gardini E, Bianconi L, Gavaruzzi G, Ugolotti G, et al. Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1992; 75: 1273–1277.","DOI":"10.1210\/jcem.75.5.1331165"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell’Unto E, et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 2007; 92: 556–562.","DOI":"10.1210\/jc.2006-2059"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. O’Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: Left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154: 533–536.","DOI":"10.1530\/eje.1.02122"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/77\/12\/77_CJ-13-0220\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T04:09:26Z","timestamp":1616645366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/77\/12\/77_CJ-13-0220\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-13-0220","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}